Clinical Trials Logo

Ocular Melanoma clinical trials

View clinical trials related to Ocular Melanoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06007690 Recruiting - Uveal Melanoma Clinical Trials

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

CoMpass
Start date: December 6, 2023
Phase: Phase 3
Study type: Interventional

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

NCT ID: NCT05628883 Recruiting - Metastatic Melanoma Clinical Trials

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Start date: November 22, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this first in human study is to evaluate the feasibility, safety, and efficacy of administering TBio-4101 (tumor infiltrating lymphocytes [TIL]) after receiving a lymphodepleting chemotherapy regimen and before receiving interleukin-2 (IL-2) in participants with unresectable or metastatic melanoma.

NCT ID: NCT05524935 Recruiting - Uveal Melanoma Clinical Trials

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Start date: October 11, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.

NCT ID: NCT03172299 Recruiting - Ocular Melanoma Clinical Trials

Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma

PROTECT
Start date: June 8, 2017
Phase: Phase 3
Study type: Interventional

The reference treatment of ocular melanoma is a conservative treatment by proton therapy. Its goal is to treat the tumor while preserving the eyeball and visual acuity. However, ablation of the eyeball is sometimes necessary after proton therapy in the case of neovascular glaucoma. This complication occurs in 7 to 47% of cases (depending on the size of the tumor) and is associated with hypersecretion of Vascular Endothelial Growth Factor (VEGF) related to necrotic and inflammatory tumor tissue after proton therapy or ischemic retina. The intravitreal injections of anti-VEGF are used in the treatment of neovascular radicular glaucoma without avoiding enucleation in all cases. The investigators propose to study the prevention of neovascular glaucoma by intravitreal prophylactic administration of anti-VEGF.

NCT ID: NCT02909517 Recruiting - Ocular Melanoma Clinical Trials

The Role of Inflammation in Ocular Tumours

Start date: March 2016
Phase:
Study type: Observational

This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: 1. Choroidal nevus 2. Choroidal indeterminate melanocytic lesion 3. Choroidal melanoma 4. Suspected metastatic tumour (ie, primary tumour elsewhere) 5. Locally treated ocular tumours

NCT ID: NCT00168870 Recruiting - Ocular Melanoma Clinical Trials

Study of Metastatic Ocular Melanoma

Start date: February 2003
Phase: Phase 2
Study type: Interventional

This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.